{"id":1100,"date":"2026-05-18T16:00:00","date_gmt":"2026-05-18T19:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=1100"},"modified":"2026-05-18T16:00:00","modified_gmt":"2026-05-18T19:00:00","slug":"pgrss-clinica-imunoterapia-oncologica-pembrolizumab-rss","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-imunoterapia-oncologica-pembrolizumab-rss\/","title":{"rendered":"PGRSS imunoterapia oncol\u00f3gica \u2014 pembrolizumab e nivolumab"},"content":{"rendered":"<h2>Por que imunoterapia tem perfil espec\u00edfico<\/h2>\n<p>Cl\u00ednica de imunoterapia oncol\u00f3gica administra <strong>anticorpos monoclonais checkpoint<\/strong> \u2014 Pembrolizumab (Keytruda), Nivolumab (Opdivo), Atezolizumab (Tecentriq), Ipilimumab (Yervoy). Diferente de QT cl\u00e1ssica (genot\u00f3xico), imunoterapia ativa o sistema imune (anti-PD-1\/PD-L1\/CTLA-4). Combina <strong>infus\u00e3o IV em ambiente classificado<\/strong> + <strong>manejo de irAE (efeitos imuno-relacionados)<\/strong> + <strong>monitoriza\u00e7\u00e3o cont\u00ednua<\/strong>. Opera sob RDC 222 + RDC 220\/2004 (anti-neopl\u00e1sicos) + RDC 6\/2015 (alta complexidade).<\/p>\n<h2>Tabela 5 fluxos<\/h2>\n<table>\n<thead>\n<tr>\n<th>Fluxo<\/th>\n<th>Grupo<\/th>\n<th>Volume mensal<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Frasco\/seringa pembrolizumab\/nivolumab<\/td>\n<td>B (anti-neopl\u00e1sico n\u00e3o-citost\u00e1tico)<\/td>\n<td>1-3 kg<\/td>\n<\/tr>\n<tr>\n<td>Equipo IV p\u00f3s-administra\u00e7\u00e3o<\/td>\n<td>A1 baixa<\/td>\n<td>3-7 kg<\/td>\n<\/tr>\n<tr>\n<td>EPI completo (luva nitr\u00edlica dupla, avental)<\/td>\n<td>A1 baixa<\/td>\n<td>2-5 kg<\/td>\n<\/tr>\n<tr>\n<td>Frasco diluente vencido<\/td>\n<td>B<\/td>\n<td>0,5-1,5 kg<\/td>\n<\/tr>\n<tr>\n<td>Material extravasamento (kit derrame)<\/td>\n<td>B (anti-neopl\u00e1sico)<\/td>\n<td>0,3-1 kg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Volume t\u00edpico: <strong>7-17 kg\/m\u00eas<\/strong>.<\/p>\n<h2>Cap\u00edtulo anti-neopl\u00e1sico n\u00e3o-citost\u00e1tico<\/h2>\n<p>Imunoterapia (anti-PD-1) N\u00c3O \u00e9 citost\u00e1tica (\u2260 QT cl\u00e1ssica), mas RDC 220\/2004 cobre TODOS anti-neopl\u00e1sicos:<\/p>\n<ul>\n<li>Manuseio em c\u00e2mara classe II (sala paramentada)<\/li>\n<li>EPI completo (luva nitr\u00edlica dupla + avental imperme\u00e1vel + m\u00e1scara PFF2)<\/li>\n<li>Funcion\u00e1ria gr\u00e1vida n\u00e3o pode manusear<\/li>\n<li>Sobra do frasco = Grupo B + manifesto MTR espec\u00edfico<\/li>\n<li>Spill kit (kit de extravasamento) obrigat\u00f3rio por sala<\/li>\n<\/ul>\n<h2>3 perfis<\/h2>\n<p><strong>Perfil 1 \u2014 Centro pequeno (1-2 imunoter\u00e1picos):<\/strong> R$ 380-800\/m\u00eas. Setup R$ 8-15k.<\/p>\n<p><strong>Perfil 2 \u2014 Centro m\u00e9dio (4-6 imunoter\u00e1picos + QT):<\/strong> R$ 800-1700\/m\u00eas. Setup R$ 15-30k.<\/p>\n<p><strong>Perfil 3 \u2014 Hospital oncol\u00f3gico avan\u00e7ado (CAR-T + bispec\u00edficos):<\/strong> R$ 1700-3500\/m\u00eas. Setup R$ 30-60k.<\/p>\n<h2>3 erros frequentes<\/h2>\n<ol>\n<li>Frasco pembrolizumab no Grupo B comum \u2014 exige rotulagem espec\u00edfica anti-neopl\u00e1sico<\/li>\n<li>EPI sem luva dupla \u2014 descumprimento RDC 220<\/li>\n<li>Sem spill kit por sala \u2014 auto VISA + suspens\u00e3o licen\u00e7a<\/li>\n<\/ol>\n<p><strong><a href=\"https:\/\/sevenresiduosaude.com.br\/orcamento\/\">Solicite cota\u00e7\u00e3o imunoterapia oncol\u00f3gica<\/a><\/strong> \u2014 cap\u00edtulo anti-neopl\u00e1sico + spill kit + EPI dupla luva.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>RSS de cl\u00ednica de imunoterapia oncol\u00f3gica: pembrolizumab, nivolumab, atezolizumab. RDC 222 + RDC 220 anti-neopl\u00e1sicos.<\/p>\n","protected":false},"author":3,"featured_media":1099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2069,1870,2070,1872],"class_list":["post-1100","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-imunoterapia","tag-oncologia","tag-pembrolizumab","tag-rdc-220"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/1100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=1100"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/1100\/revisions"}],"predecessor-version":[{"id":3561,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/1100\/revisions\/3561"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/1099"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=1100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=1100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=1100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}